This review examines the relationship between postmenopausal hormone therapy (HT) and breast cancer risk, analyzing data from various studies. Findings suggest that combined estrogen-progestogen therapy is associated with a higher risk of breast cancer than estrogen-only therapy, with risk increasing with duration of use and decreasing after discontinuation. The type
